Understanding Herpes Simplex Infections

From prevalence to pipeline—our infographic breaks it down!: Click Here

Herpes Simplex Epidemiological Segmentation

The epidemiological analysis of Herpes Simplex in the 7MM from 2020 to 2034 includes:

Herpes Simplex Epidemiology

In 2023, Herpes Simplex prevalence showed distinct patterns across the 7MM:

Around 13.04 million diagnosed cases of HSV were reported across the 7MM, with approximately 4.95 million cases in the United States. This number is projected to decline throughout the study period.
Female-diagnosed cases were higher than male-diagnosed cases across the 7MM, with women comprising 55% of the total diagnosed population.
In Japan, there were an estimated 1.56 million diagnosed cases of HSV in 2023—700,000 among males and 856,000 among females. These figures are also expected to decrease during the forecast period.

Numbers tell part of the story—get the full analysis in our report: Click Here

Herpes Simplex Market

In 2023, the total market size for Herpes Simplex in the 7MM was valued at approximately USD 3.1 billion.

Herpes Simplex Market Drivers

The advancement of novel antiviral therapies such as PRITELIVIR (AIC-316) and mRNA-1608 presents promising opportunities for improved HSV management and reduction in recurrence rates.
Enhanced awareness and progress in diagnostic technologies are anticipated to facilitate better identification and treatment of symptomatic HSV cases, supporting market growth.

The unpredictable nature of HSV outbreaks and variability in treatment response pose challenges to effective disease management and the development of standardized treatment protocols.
Limited accessibility and high costs of novel antiviral agents may restrict their adoption, especially in low-resource settings, hindering broader market expansion.

Herpes Simplex Emerging Therapies